Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important categories such as germinal center B (GCB)-like and non-GCB-like groups. The t(14;18)(q32;q21) translocation defines a unique subset of DLBCL cases with a GCB gene expression profile. Two-color fluorescence in situ hybridization (FISH) analysis was applied to detect t(14;18) (q32;q21) in the nuclei of paraffin-embedded tissue sections from 61 patients with de novo DLBCL. Nine (15%) of 61 cases had a positive pattern. Fifty-seven cases were subclassified in an immunohistochemical study with anti-CD10, anti-bcl-6, and anti-MUM1 antibodies. In this classification, 21 cases (37%) were placed in the GCB group, and 36 (63%) were placed in the non-GCB group. There was a discrepancy between t(14;18) occurrence and bcl-2 protein expression. Bcl-2 protein expression was positive in 40 (67%) of 60 cases. The expression of bcl-2 protein in the GCB and non-GCB groups was not significantly different: 15 (71%) of 21 cases in the GCB group and 24 (67%) of 36 cases in the non-GCB group tested positive. We found no difference between the FISH-positive and FISH-negative groups in overall survival time (P = .6019, log-rank test). The overall survival rates of GCB and non-GCB groups did not differ significantly by immunohistochemical classification (P = .5399, log-rank test). Overall survival was significantly longer in the group with a low International Prognostic Index (IPI) score than in the group with a high IPI score (P = .0002, log-rank test). Our results suggest that immunohistochemical study and cytogenetic study with t(14;18) FISH cannot predict the clinical outcomes of DLBCL patients. A study with a larger number of patients may show a difference in clinical outcomes between FISH-positive and FISH-negative groups and between GCB and non-GCB groups.
Hirose
Yuko
Y
Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan. y-hirose@kanazawa-med.ac.jp
Masaki
Yasufumi
Y
Karasawa
Hiromi
H
Shimoyama
Kumiko
K
Fukushima
Toshihiro
T
Kawabata
Hiroshi
H
Ogawa
Noriyoshi
N
Wano
Yuji
Y
Ozaki
Mamoru
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002883:Chromosomes, Human, Pair 14; D002887:Chromosomes, Human, Pair 18; D005260:Female; D018858:Germinal Center / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D015994:Incidence; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014178:Translocation, Genetic
N Engl J Med. 1993 Sep 30;329(14 ):987-94
8141877
Blood. 2004 Jan 1;103(1):275-82
14504078
Blood. 2003 Jul 1;102(1):324-7
12649152
Cancer Res. 1992 Oct 1;52(19 Suppl):5529s-5540s
1394168
Nat Med. 2002 Jan;8(1):68-74
11786909
Cancer. 1993 Jul 1;72(1):231-6
8508412
Cancer Genet Cytogenet. 2004 Apr 1;150(1):22-6
15041219
Br J Haematol. 1998 Nov;103(2):495-504
9827925
Blood. 2003 Jun 1;101(11):4279-84
12576316
Semin Hematol. 2000 Oct;37(4):396-411
11071361
Hum Pathol. 2002 Oct;33(10):968-74
12395368
N Engl J Med. 1989 Apr 20;320(16):1047-54
2648153
Blood. 2002 Apr 1;99(7):2285-90
11895757
Leukemia. 2000 Mar;14(3):449-56
10720141
N Engl J Med. 1987 Nov 5;317(19):1185-9
3657890
Mod Pathol. 2001 Jul;14(7):686-94
11455001
Pathol Int. 2000 Sep;50(9):696-702
11012982
Blood. 1998 Nov 1;92(9):3152-62
9787151
Nature. 2000 Feb 3;403(6769):503-11
10676951
Int J Hematol. 2003 Aug;78(2):154-9
12953811
Genes Chromosomes Cancer. 1999 Jun;25(2):123-33
10337996
N Engl J Med. 2002 Jun 20;346(25):1937-47
12075054
Mod Pathol. 2002 Dec;15(12):1366-73
12481019
J Clin Oncol. 1994 Jan;12(1):149-54
8270971
Blood. 2003 Jan 1;101(1):78-84
12393466
Am J Surg Pathol. 2000 Jun;24(6):846-52
10843287